A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
January 1, 2015
End Date
June 30, 2025
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
January 1, 2015
End Date
June 30, 2025